Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 17.06.
Amivantamab-lazertinib beter dan osimertinib bij NSCLC met EGFR-mutatie
feb 2026 | Longoncologie